KLK3 and posterior cortical atrophy: At 6 months (6th dose of DCVAC/PCa) after the initiation of chemo/immunotherapy, a ≥ 50% decrease in PSA was observed in 8 of 23 patients (34, 8%) and 25–50% decrease of PSA in additional 5 patients (21, 7%).